Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis

https://doi.org/10.1016/j.neulet.2008.02.064Get rights and content

Abstract

Axonal degeneration is now recognized as an important pathological feature of multiple sclerosis (MS). Acute axonal damage happens early in the disease course, and therefore early changes might occur in markers in body fluids, such as cerebrospinal fluid (CSF) and blood. In our study we investigated the relevance of serum and CSF markers for axonal damage in patients with clinically isolated syndrome indicative for MS. We measured the concentration of tau, phospho-tau, S100B, Amyloid beta and neuron specific enolase (NSE) in CSF and serum. Interestingly, the NSE concentration in CSF and serum was decreased in clinically isolated syndrome (CIS)-patients in comparison to the control group indicating reduced neuronal metabolic activity in the early stage of the disease. Concerning other biomarkers, we did not observe any changes in the concentrations between groups. Moreover, we did not detect any correlation between Expanded Disability Status Scale (EDSS) and the concentration of investigated proteins.

Section snippets

Acknowledgements

This work was supported by the Medical Faculty of the University of Göttingen, Germany (junior research group; R. D.), the Gemeinnützige Hertie Foundation, and by a research grant from Bayer Vital GmbH.

References (38)

  • M. Colucci et al.

    The 14-3-3 protein in multiple sclerosis: a marker of disease severity

    Mult. Scler.

    (2004)
  • J. de Seze et al.

    14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis

    J. Neurol.

    (2002)
  • N. De Stefano et al.

    Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study

    Brain

    (1998)
  • G. Franz et al.

    Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury

    Neurology

    (2003)
  • I. Guimaraes et al.

    Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis

    Mult. Scler.

    (2006)
  • H. Hampel et al.

    Core biological marker candidates of Alzheimer's disease—perspectives for diagnosis, prediction of outcome and reflection of biological activity

    J. Neural. Transm.

    (2004)
  • E.C. Jauch et al.

    Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study

    Stroke

    (2006)
  • K. Jendroska et al.

    Amyloid beta-peptide and the dementia of Parkinson's disease

    Mov. Disord.

    (1996)
  • F.J. Jimenez-Jimenez et al.

    Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis

    Acta Neurol. Scand.

    (2002)
  • Cited by (61)

    • Neutrophil activity in serum as a biomarker for multiple sclerosis

      2023, Multiple Sclerosis and Related Disorders
    • Serum and saliva total tau protein as a marker for relapsing-remitting multiple sclerosis

      2020, Medical Hypotheses
      Citation Excerpt :

      They showed that serum tau protein level was higher in MS patients than control individuals. However, in other studies, there was no significant difference in CSF tau protein between the two groups [2,6,9,19,20]. Serum total tau protein in our study was in contrast of the above reports in MS women.

    View all citing articles on Scopus
    View full text